KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Debt Issuances (2020 - 2025)

Historic Long-Term Debt Issuances for Alnylam Pharmaceuticals (ALNY) over the last 4 years, with Q4 2025 value amounting to -$680000.0.

  • Alnylam Pharmaceuticals' Long-Term Debt Issuances changed N/A to -$680000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.5 million, marking a year-over-year decrease of 10014.34%. This contributed to the annual value of $645.7 million for FY2025, which is N/A changed from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Long-Term Debt Issuances of -$680000.0 as of Q4 2025.
  • Alnylam Pharmaceuticals' Long-Term Debt Issuances' 5-year high stood at $1.0 billion during Q3 2022, with a 5-year trough of -$250.0 million in Q3 2021.
  • Its 3-year average for Long-Term Debt Issuances is $191.4 million, with a median of -$728500.0 in 2022.
  • Over the last 5 years, Alnylam Pharmaceuticals' Long-Term Debt Issuances had its largest YoY gain of 50675.52% in 2022, and its largest YoY loss of 50675.52% in 2022.
  • Over the past 3 years, Alnylam Pharmaceuticals' Long-Term Debt Issuances (Quarter) stood at -$250.0 million in 2021, then skyrocketed by 99.69% to -$777000.0 in 2022, then increased by 12.48% to -$680000.0 in 2025.
  • Its Long-Term Debt Issuances was -$680000.0 in Q4 2025, compared to -$777000.0 in Q4 2022 and $1.0 billion in Q3 2022.